Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia

Authors

  • Beatriz Carvalho Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • Paulo Freitas-Costa Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • João Pinheiro-Costa Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • Manuel Falcão Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • Ângela Carneiro Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.
  • Fernando Falcão-Reis Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

DOI:

https://doi.org/10.20344/amp.2038

Abstract

Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes.
Material and Methods: In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment.
Results: The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9μm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001).
Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.

Downloads

Download data is not yet available.

Author Biographies

Beatriz Carvalho, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Paulo Freitas-Costa, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

João Pinheiro-Costa, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Manuel Falcão, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Ângela Carneiro, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Fernando Falcão-Reis, Departamento de Oftalmologia. Hospital de São João/Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Published

2014-01-08

How to Cite

1.
Carvalho B, Freitas-Costa P, Pinheiro-Costa J, Falcão M, Carneiro Ângela, Falcão-Reis F. Evaluation of Antiangiogenic Treatment Results in Choroidal Neovascularization Related to Pathological Myopia. Acta Med Port [Internet]. 2014 Jan. 8 [cited 2024 Mar. 29];27(1):49-58. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/2038